皮下注射奥马珠单抗成功治疗重度春季角结膜炎。

Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab.

作者信息

de Klerk Timothy A, Sharma Vibha, Arkwright Peter D, Biswas Susmito

机构信息

Manchester Royal Eye Hospital, Manchester, United Kingdom.

出版信息

J AAPOS. 2013 Jun;17(3):305-6. doi: 10.1016/j.jaapos.2012.12.153. Epub 2013 Apr 19.

DOI:10.1016/j.jaapos.2012.12.153

PMID:23607979

Abstract

A 12-year-old boy with severe mixed limbal and palpebral vernal keratoconjunctivitis experienced persistent ocular symptoms despite treatment with topical corticosteroids or cyclosporine. Signs and symptoms resolved completely with monthly subcutaneous omalizumab, an immunomodulating biologic agent. To our knowledge, this is the first report of its use as a monotherapy agent to treat vernal keratoconjunctivitis.

摘要

一名患有严重混合型角膜缘和睑结膜春季角结膜炎的12岁男孩，尽管使用了局部皮质类固醇或环孢素治疗，眼部症状仍持续存在。使用免疫调节生物制剂奥马珠单抗每月皮下注射一次后，体征和症状完全消失。据我们所知，这是将其作为单一治疗药物治疗春季角结膜炎的首例报告。